Graphite Bio Banner Image

Graphite Bio

  • Ticker GRPH
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Graphite Bio Logo Image
  • 51-200 Employees
  • Based in South San Francisco, California
Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. GraphiteMore Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology-directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. Additionally, the company is advancing the development of novel conditioning regimens to help bring curative therapies to more patients.
Graphite Bio

Most Recent Annual Report

Graphite Bio
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Graphite Bio Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!